Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

The selling price is an indication that the FDA’s planned sunsetting of the rare pediatric disease voucher program may be ...

Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is ...

Quantiphi Global Head of Healthcare and Life Sciences Barinder Marhok said the partnership marries DDReg’s expertise in ...

Novo and Lilly are racing to build on their dominant obesity drug businesses. Both are working to broaden use of their therapies, while also working on newer medications that are meant to be more ...

Just three years removed from a lucrative IPO, the company will cut jobs for a third time and invest more heavily in cell ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of ...

For a small rare disease company with a treatment in the clinic, the toughest challenge isn’t necessarily the science. Often, ...

The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett ...

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...

Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...

The quality of digital PCR data can only be as high as the assays used to obtain it. High-quality assays ensure that the ...